Further evidence for the role of TLR2 and TLR4 in CVB3 myocarditis was obtained by treating male and female C57Bl/6 mice with either 50μg PAM3CSK4 (PAM; TLR2 agonist) or 20 mg/kg Ultra-Pure LPS (UP-LPS; TLR4 agonist). This evidence concerns the gene TLR4 and myocarditis.